A Prospective Study to Examine the Need to Adjust the Dose of Apixaban When Used in Atrial Fibrillation and Obesity

NCT03893591 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 82

Last updated 2020-04-01

No results posted yet for this study

Summary

A prospective cohort study to determine whether a high body weight (BMI equal to or greater than 35 kg / m 2) has an effect on anticoagulant Apixaban level in the blood of patients with atrial fibrillation.

Conditions

Interventions

DIAGNOSTIC_TEST

Anti Xa levels

one Blood sample

Sponsors & Collaborators

  • HaEmek Medical Center, Israel

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-06
Primary Completion
2020-02-29
Completion
2020-02-29

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03893591 on ClinicalTrials.gov